Combination of radiotherapy and chemotherapy in locally advanced NSCLC

Expert Review of Anticancer Therapy

Volumn 9, Issue 10, 2009, Pages 1389-1403

  Kepka, Lucyna ^a   Sprawka, Arkadiusz ^a   Casas, Francesc ^b   Abdel Wahab, Sherif ^c   Agarwal, Jai Prakash ^d   Jeremic, Branislav ^e  

^a INSTITUTE OF ONCOLOGY   (Poland)

^b HOSPITAL CLÍNIC   (Spain)

^c AIN SHAMS UNIVERSITY   (Egypt)

^d TATA MEMORIAL HOSPITAL   (India)

^e Institute of Pulmonary Diseases   (Serbia)

Author keywords

Amifostine; Chemotherapy; EGFR inhibitors; Locally advanced NSCLC; Radiochemotherapy; Radiotherapy; Randomized study

Indexed keywords

AMIFOSTINE; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ETOPOSIDE; GEFITINIB; GEMCITABINE; IFOSFAMIDE; LOMUSTINE; METHOTREXATE; MITOMYCIN; NAVELBINE; PACLITAXEL; PLACEBO; PLATINUM COMPLEX; PROCARBAZINE; THALIDOMIDE; VASCULOTROPIN INHIBITOR; VINBLASTINE; VINDESINE;

ADJUVANT THERAPY; ADVANCED CANCER; AREA UNDER THE CURVE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER RESISTANCE; CANCER STAGING; CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG CHOICE; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG SAFETY; EMBOLISM; HUMAN; IONIZING RADIATION; LEUKEMIA; LOW DRUG DOSE; LUNG LOBECTOMY; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; METASTASIS; MICROMETASTASIS; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RADIATION HAZARD; RADIATION INJURY; RADIATION RESPONSE; RADIOSENSITIZATION; REVIEW; THROMBOSIS; TREATMENT FAILURE; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; HUMANS; LUNG NEOPLASMS; NEOPLASM STAGING; RADIATION INJURIES; SURVIVAL RATE;

EID: 70350589044     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/ERA.09.121     Document Type: Review

References (90)

1. Robinson LA, Ruckdeschel JC, Wagner H Jr, Stevens CW. Treatment of non-small cell lung cancer-stage IIIA: ACCP evidence-based clinical practice guidelines (2nd Edition). Chest 132(3 Suppl.), 243S-265S (2007).
2. Jett JR, Schild SE, Keith RL, Kesler KA. Treatment of non-small cell lung cancer-stage IIIB: ACCP evidence-based clinical practice guidelines (2nd Edition). Chest 132(3), 266S-76S (2007).
3. Rowell NP, O'Rourke NP. Concurrent chemoradiotherapy in non-small cell lung cancer. Cochrane Database Syst. Rev. 4, CD002140 (2004). •• Detailed overview and meta-analysis of trials aiming to determine a benefit of concurrent radiochemotherapy (RT-CHT) over radiotherapy (RT) alone and concurrent versus sequential approach.
4. Auperin A, Rolland E, Walter C et al. Concomitant radio-chemotherapy (RT-CT) versus sequential RT-CT in locally advanced non-small cell lung cancer (NSCLC): a meta-analysis using individual patient data (IPD) from randomised clinical trials. J. Thorac. Oncol. 2(8 Suppl.4), 309S (2007).
5. Kong FM, Gaspar LE, Komaki R et al. Patterns of practice in radiation dose prescription and treatment planning for patients with lung cancer among members of american society of therapeutic radiology and oncology. Int. J. Radiat. Oncol. Biol. Phys. 69(3 Suppl.), 483S (2007).
6. Widder J, De Ruysscher D, Senan S et al. Patterns of practice survey for radiation therapy in lung cancer among ESTRO members. Radiother. Oncol. 88(Suppl.2), 38S (2008).
7. De Ruysscher D, Botterweck A, Dirx M et al. Eligibility for concurrent chemotherapy and radiotherapy of locally advanced lung cancer patients: a prospective, population-based study. Ann. Oncol. 20 (1), 98-102 (2009). • Prospective trial demonstrating a low availability of non-small-cell lung cancer (NSCLC) patients for concurrent approach in developed world.
8. Kepka L, Danilova V, Saghatelyan T et al. Resources and management strategies for the use of radiotherapy in the treatment of lung cancer in Central and Eastern European countries: results of an International Atomic Energy Agency (IAEA) survey. Lung Cancer 56(2), 235-245 (2007). (Pubitemid 46591989)
9. Arriagada R, Le Chevalier T, Quoix E et al. ASTRO (American Society for Therapeutic Radiology and Oncology) plenary: effect of chemotherapy on locally advanced non-small cell lung carcinoma: a randomized study of 353 patients. GETCB (Groupe d'Etude et Traitement des Cancers Bronchiques), FNCLCC (Féderation Nationale des Centres de Lutte contre le Cancer) and the CEBI trialists. Int. J. Radiat. Oncol. Biol. Phys. 20(6), 1183-1190 (1991).
10. Byhardt RW, Scott C, Sause WT et al. Response, toxicity, failure patterns, and survival in five Radiation Therapy Oncology group (RTOG) trials of sequential and/or concurrent chemotherapy and radiotherapy for locally advanced non-small-cell carcinoma of the lung. Int. J. Radiat. Oncol. Biol. Phys. 42 (3), 469-478 (1998). (Pubitemid 28501093)
11. Steel GG. Terminology in the description of drug-radiation interactions. Int. J. Radiat. Oncol. Biol. Phys. 5(8), 1145-1150 (1979).
12. Wilson GD, Bentzen S, Harari PM. Biologic basis for combining drugs with radiation. Semin. Radiat. Oncol. 16(1), 2-9 (2006). • Overview of rationale and molecular mechanisms of combined treatment. (Pubitemid 41832311)
13. Dillman RO, Herndon J, Seagren SL et al. Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of Cancer and Leukemia group B [CALGB] 8433 trial. J. Natl Cancer Inst. 88(17), 1210-1214 (1996). (Pubitemid 26302034)
14. Sause W, Kolesar P, Taylor S IV et al. Final results of Phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology group, Eastern Cooperative Oncology group, and Southwest Oncology group. Chest 117(2), 358-364 (2000). (Pubitemid 30111583)
15. Arriagada R, Le Chevalier T, Rekacewicz E et al. Cisplatin-based chemotherapy (CT) in patients with locally advanced non-small cell lung cancer (NSCLC): late analysis of a French randomized trial. Proceedings of ASCO. J. Clin. Oncol. 16, A446 (1997).
16. Cullen MH, Billingham LJ, Woodroffe CM et al. Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life. J. Clin. Oncol. 17(10), 3188-3194 (1999).
17. Non-small cell lung cancer collaborative group: chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized trials. Br. Med. J. 311(7010), 899-909 (1995).
18. Rolland E, Le Chevalier T, Auperin A et al. Sequential radio-chemotherapy (RT-CT) versus radiotherapy alone (RT) and concomitant RT-CT versus RT alone in locally advanced non-small cell lung cancer (NSCLC): two meta-analyzes using individual patent data (IPD) from randomised clinical Trials (RCTs). J. Thorac. Oncol. 2(8 Suppl. 4), 309S (2007).
19. Soresi E, Clerici M, Grilli R et al. A randomized clinical trial comparing radiation therapy versus radiation therapy plus cis-dichlorodiamine platinum (II) in the treatment of locally advanced non small cell lung cancer. Semin. Oncol. 15(Suppl. 7), 20-25 (1988). (Pubitemid 19059385)
20. Trovo MG, Minatel E, Veronesi A et al. Combined radiotherapy and chemotherapy versus radiotherapy alone in locally advanced epidermoid bronchogenic carcinoma: a randomized study. Cancer 65(3), 400-404 (1990).
21. Trovo MG, Minatel E, Franchin G et al. Radiotherapy versus radiotherapy enhanced by cisplatin in stage III non small cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 24(1), 11-15 (1992).
22. Schaake-Koning C, Van den Bogaert W, Dalesio O et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small cell lung cancer. N. Engl. J. Med. 326(8), 524-530 (1992).
23. Jeremic B, Shibamoto Y, Acimovic L, Djuric L. Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small-cell lung cancer. J. Clin. Oncol. 13(2), 452-458 (1995).
24. Jeremic B, Shibamoto Y, Milicic B, Milisavljevic S. Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/ etoposide for stage III non-small-cell lung cancer: a randomized study. J. Clin. Oncol. 14(4), 1065-1070 (1996). (Pubitemid 26105510)
25. Bonner JA, McGinnis WL, Stella PJ et al. The possible advantage of hyperfractionated thoracic radiotherapy in the treatment of locally advanced nonsmall cell lung carcinoma: results of a North Central Cancer Treatment group Phase III study. Cancer 82(6), 1037-1048 (1998).
26. Blanke C, Ansari R, Montravadi R et al. A Phase III trial of thoracic irradiation with and without concomitant cisplatin for locally advanced unresectable non small cell lung cancer: a Hoosier Oncology group study. J. Clin. Oncol. 13(6), 1425-1429 (1995).
27. Ball D, Bishop J, Smith J et al. A randomized Phase III study of accelerated or standard fraction radiotherapy with or without concurrent carboplatin in inoperable non-small cell lung cancer: final report of an Australian multi-centre trial. Radiother. Oncol. 52(2), 129-136 (1999). (Pubitemid 29461080)
28. Clamon G, Herndon J, Cooper R, Chang AY, Rosenman J, Green MR. Radiosensitization with carboplatin for patients with unresectable stage III non-small-cell lung cancer: a Phase III trial of the Cancer and Leukemia group B and the Eastern Cooperative Oncology group. J. Clin. Oncol. 17(1), 4-11 (1999). (Pubitemid 29022371)
29. Groen HJ, Van der Leest AH, Fokkema E et al. Continuously infused carboplatin used as radiosensitizer in locally unresectable non-small-cell lung cancer: a multicenter Phase III study. Ann. Oncol. 15(3), 427-432 (2004). (Pubitemid 38444545)
30. Cakir S, Egehan I. A randomised clinical trial of radiotherapy plus cisplatin versus radiotherapy alone in stage III non-small cell lung cancer. Lung Cancer 43(3), 309-316 (2004). (Pubitemid 38224151)
31. Aupérin A, Le Péchoux C, Pignon JP et al. Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC): a meta-analysis of individual data from 1764 patients. Ann. Oncol. 17(3), 473-483 (2006). •• Detailed overview and fully published meta-analysis demonstrating a benefit of concomitant RT-CHT over RT alone. (Pubitemid 43329586)
32. Furuse K, Fukuoka M, Kawahara M et al. Phase III study of concurrent vs. sequential thoracic radiotherapy in combination with mitomycin, vindesine and cisplatin in unresectable stage III non-small cell lung cancer: five-year median follow-up results. J. Clin. Oncol. 17(9), 2692-2699 (1999). (Pubitemid 29415225)
33. Curran WJ, Scott CB, Langer CJ et al. Long-term benefit is observed in a Phase III comparison of sequential vs concurrent chemo-radiation for patients with unresected stage NSCLC: RTOG 9410. J. Clin. Oncol. 22(Suppl.), 621S (2003).
34. Zatloukal P, Petruzelka L, Zemanowa M et al. Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study. Lung Cancer 46(1), 87-98 (2004). (Pubitemid 39201387)
35. Fournel P, Robinet G, Thomas P et al. Randomized Phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Francais de Pneumo-Cancerologie NPC 95-01 Study. J. Clin. Oncol. 23(25), 5910-5917 (2005). • Fully published completed trial comparing sequential and concurrent RT-CHT with modern approach to both modalities in NSCLC. (Pubitemid 46300207)
36. Belderbos JSA, Uitterhoeve LLJ, van Zandwijk N et al. Randomised trial of sequential versus concurrent chemoradiotherapy in patients with inoperable non-small cell lung cancer (EORTC 08972-22973). Eur. J. Cancer 43(1), 114-121 (2007). (Pubitemid 46054477)
37. Vokes EE, Herndon JE, Kelley MJ et al. Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III non-small-cell lung cancer: Cancer and Leukemia Group B. J. Clin. Oncol. 25(13),1698-1704 (2007).
38. Kim MK, Kim SW, Choi EK et al. Induction chemotherapy followed by concurrent chemoradiotherapy (CCRT) versus CCRT alone for unresectable stage III non-small cell lung cancer (NSCLC): randomized Phase III trial. J. Thorac. Oncol. 2(8 Suppl. 4), 308S (2007).
39. Huber RM, Flentje M, Schmidt M et al. Simultaneous chemoradiation compared with radiotherapy alone after induction chemotherapy in inoperable stage IIIA or IIIB non-small- cell lung cancer: Study CTRT99/97 by the Bronchial Carcinoma Therapy group. J. Clin. Oncol. 24(27), 4397-4404 (2006). (Pubitemid 46630977)
40. Hanna NH, Neubauer M, Ansari R et al. Phase III trial of cisplatin (P) plus etoposide (E) plus concurrent chest radiation (XRT) with or without consolidation docetaxel (D) in patients (pts) with inoperable stage III non-small cell lung cancer (NSCLC): HOG LUN 01-24/USO-023. J. Clin. Oncol. 25(Suppl. 18), 387 (2007).
41. Kelly K, Chansky K, Gaspar LE et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small cell lung cancer: SWOG S0023. J. Clin. Oncol. 26(15), 2450-2456 (2008).
42. Andre F, Grunenwald D, Pignon JP et al. Survival of patients with resected N2 non-small-cell lung cancer: evidence for a subclassification and implications. J. Clin. Oncol. 18(16), 2981-2989 (2000). (Pubitemid 30644122)
43. Albain KS, Swann RS, Rusch VR et al. Phase III study of concurrent chemotherapy and radiotherapy (CT/RT) vs CT/RT followed by surgical resection for stage IIIA (pN2) non-small cell lung cancer (NSCLC): outcomes update of North American Intergroup 0139 (RTOG 9309). J. Clin. Oncol. 23(Suppl.) 624S (2005).
44. Thomas M, Rube C, Hoffknecht P et al. Effect of preoperative chemoradiation in addition to preoperative chemotherapy: a randomised trial in stage III non-small-cell lung cancer. Lancet Oncol. 9(7), 636-648 (2008).
45. Van Meerbeck JP, Kramer GWPM, Van Schil PEY et al. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small cell lung cancer. J. Natl Cancer Inst. 99(6), 442-450 (2007).
46. Wang S, Liao Z, Wei X et al. Analysis of clinical and dosimetric factors associated with treatment-related pneumonitis (TRP) in patients with non-small call lung cancer (NSCLC) treated with concurrent chemotherapy and three-dimensional conformal radiotherapy (3D-CRT). Int. J. Radiat. Oncol. Biol. Phys. 66(5), 1399-1407 (2006). (Pubitemid 44778943)
47. Rigas JR, Kelly K. Current treatment paradigms for locally advanced non-small cell lung cancer. J. Thorac. Oncol. 2(6 Suppl. 2), S77-S85 (2007). (Pubitemid 46988097)
48. Baggstrom MQ, Stinchcombe TE, Fried DB, Poole C, Hensing TA, Socinski MA. Third generation chemotherapy agents in the treatment of advanced non-small cell lung cancer: a meta-analysis. J. Thorac. Oncol. 2(9), 845-853 (2007). (Pubitemid 47361027)
49. Scalliet P, Goor C, Galdermans D et al. Gemzar (gemcitabine) with thoracic radiotherapy - a Phase II pilot study in chemonaive patients with advanced non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol. 17, 499a (1998) (Abstract 1923).
50. Delbaldo C, Michiels S, Syz N, Soria JC, Le Chevalier , Pignon JB. Second or third additional chemotherapy drug for non-small cell lung cancer in patients with advanced disease. Cochrane Database Syst. Rev. 17(4), CD004569 (2007). (Pubitemid 351805366)
51. Berghmans T, Van Houtte P, Paesmans M et al. A Phase III randomised study comparing concomitant radiochemotherapy as induction versus consolidation treatment in patients with locally advanced unresectable non-small cell lung cancer. Lung Cancer 64(2), 187-193 (2009).
52. Shepherd FA, Pereira JR, Ciuleanu T et al. Erlotinib in previously treated non-small cell lung cancer. N. Engl. J. Med. 353(2), 123-132 (2005). (Pubitemid 41058344)
53. Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small cell lung cancer. N. Engl. J. Med. 355(24), 2542-2550 (2006). (Pubitemid 44917502)
54. Huang SM, Harari PM. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin. Cancer Res. 6(6), 2166-2174 (2000).
55. Rishin D, Burmeister B, Mitchell P et al. Phase I trial of gefitinib (ZD1839) in combination with concurrent carboplatin, paclitaxel and radiation therapy in patients with stage III non-small cell lung cancer. J. Clin. Oncol. 22(14S), 7077 (2004).
56. Hoffman PC, Mauer AM, Haraf DC, Lester EP, Szeto LL, Vokes EE. A Phase I study of erlotinib in combination with chemoradiation for unresectable, locally advanced non-small cell lung cancer. J. Clin. Oncol. 23(16S), 648S (2005).
57. Werner-Wasik M, Swan M, Curran W et al. A Phase II study of cetuximab in combination with chemoradiation in patients with stage IIIA/B non-small cell lung cancer: an interim overall toxicity report of the RTOG 0324 trial. J. Clin. Oncol. 23(16S), 654S (2005).
58. Ready N, Janne P, Herndon J et al. Chemoradiotherapy and gefitinib in stage III non-small cell lung cancer: a CALGB stratified Phase II trial. J. Clin. Oncol. 24(18S), 375S (2006).
59. Schiller JH, Dahlberg SE, Mehta M, Johnson DH. A Phase III trial of carboplatin, paclitaxel, and thoracic radiation therapy with or without thalidomide in patients with stage III non-small cell carcinoma of the lung (NSCLC): E3598. J. Clin. Oncol. 27(15S) (2009).
60. Guida C, Maione P, Rossi A et al. Combined chemo-radiotherapy for locally advanced non-small cell lung cancer: current status and future developments. Crit. Rev. Oncol. Hematol. 68(3), 222-232 (2008).
61. Komaki R, Seiferheld W, Curran W et al. Sequential vs. concurrent chemotherapy and radiation therapy for inoperable non-small cell lung cancer (NSCLC): Analysis of failures in a Phase III study (RTOG 9410). Proc. Am. Soc. Ther. Radiol. Oncol. 42, 113 (2000).
62. Saunders M, Dische S, Barrett A, Harvey A, Griffiths G, Palmer M. Continuous, Hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multicentre trial. CHART Steering committee. Radiother. Oncol. 52(2), 137-148 (1999). (Pubitemid 29461081)
63. Baumann M, Herrmann T, Koch R et al. Continuous hyperfractionated accelerated radiotherapy - weekend less (CHARTWEL) versus conventionally fractionated (CF) in non-small-cell lung cancer (NSCLC): first results of a Phase III randomised multicentre trial (ARO 97-91). Eur. J. Cancer 3(Suppl.), S323 (2005).
64. Machtay M, Hsu C, Komaki R et al. Effect of overall treatment time on outcome after concurrent chemoradiation for locally advanced non-small cell lung carcinoma: analysis of the Radiation Therapy Oncology group (RTOG) experience. Int. J. Radiat. Oncol. Biol. Phys. 63(3), 667-671 (2005). (Pubitemid 41400050)
65. Belani CP, Wang W, Johnson DH et al. Phase III study of the Eastern Cooperative Oncology Group (ECOG 2597): induction chemotherapy followed by either standard thoracic radiotherapy or hyperfractionated accelerated radiotherapy for patients with unresectable stage IIIA and B non-small cell lung cancer. J. Clin. Oncol. 23(16), 3760-3767 (2005). (Pubitemid 46252472)
66. Uitterhoeve LLJ, Belderbos JSA, Koolen MGJ et al. Toxicity of high dose radiotherapy combined with daily cisplatin in non-small cell lung cancer: results of the EORTC 08912 Phase I/II study. Eur. J. Cancer 36 (5), 592-600 (2000).
67. Kepka L, Tyc-Szczepaniak D, Bujko K. Dose-per-fraction escalation of accelerated hypofractionated three-dimensional conformal radiotherapy in locally advanced non-small cell lung cancer. J. Thorac. Oncol. 4(7), 853-861 (2009).
68. Bradley JD, Graham M, Suzanne S et al. Phase I results of RTOG L-0117; a Phase I/II dose intensification study using 3DCRT and concurrent chemotherapy for patients with inoperable NSCLC. J. Clin. Oncol. 23(Suppl. 16), 7063S (2005).
69. Timmerman R, McGarry K, Yiannoutsos C et al. Excessive toxicity when treating central tumors in a Phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J. Clin. Oncol. 24(30), 4833-4890 (2006). (Pubitemid 46630909)
70. Belderbos JSA, Kepka L, Spring Kong F-M, Martel MK, Videtic GMM, Jeremic B. Report from the International Atomic Energy Agency (IAEA) consultants' meeting on elective nodal irradiation in lung cancer: non-small cell lung cancer (NSCLC). Int. J. Radiat. Oncol. Biol. Phys. 72(2), 335-342 (2008). • Critical overview of treatment volume in radiotherapy, also used in combination with chemotherapy.
71. Videtic GM, Rice TW, Murthy S et al. Utility of positron emission tomography compared with mediastinoscopy for delineating involved lymph nodes in stage III lung cancer: insights for radiotherapy planning from a surgical cohort. Int. J. Radiat. Oncol. Biol. Phys. 72(3), 702-706 (2008). • Interesting study demonstrating lower than expected sensitivity of PET findings in locally advanced NSCLC.
72. Kepka L, Bujko K, Zolciak-Siwinska A. Risk of isolated nodal failure for non-small cell lung cancer (NSCLC) treated with the elective nodal irradiation (ENI) using 3D-conformal radiotherapy (3D-CRT) techniques. Acta Oncol. 47(1), 95-103 (2008).
73. Yuan S, Sun X, Li M et al. A randomized study of involved-field irradiation versus elective nodal irradiation in combination with concurrent chemotherapy for inoperable stage III nonsmall cell lung cancer. Am. J. Clin. Oncol. 30(3), 239-244 (2007). (Pubitemid 46884142)
74. Perez CA, Pajak TF, Rubin P et al. Long-term observations of the pattern of failure in patients with unresectable non-oat cell carcinoma of the lung treated with definitive radiotherapy: report by the Radiation Therapy Oncology group. Cancer 59(11), 1874-1881 (1987).
75. Rosenman JG, Halle JS, Socinski MA et al. High-dose conformal radiotherapy for treatment of stage IIIA/IIIB non-small-cell lung cancer: technical issues and results of a Phase I/II trial. Int. J. Radiat. Oncol. Biol. Phys. 54(2), 348-356 (2002).
76. Stinchcombe TE, Morris DE, Lee CB et al. Induction chemotherapy with carboplatin, irinotecan, and paclitaxel followed by high dose three-dimension conformal thoracic radiotherapy (74 Gy) with concurrent carboplatin, paclitaxel, and gefitinib in unresectable stage IIIA and stage IIIB non-small cell lung cancer. J. Thorac. Oncol. 3(3), 250-257 (2008).
77. Culy CR, Spencer CM. Amifostine: an update on its clinical status as a cytoprotectant in patients with cancer receiving chemotherapy or radiotherapy and its potential therapeutic application in myelodysplastic syndrome. Drugs 61(5), 641-684 (2001).
78. Mell LK, Malik R, Komaki R et al. of amifostine on response rates in locally advanced non-small-cell lung cancer patients treated on randomized controlled trials: a meta-analysis. Int. J. Radiat. Oncol. Biol. Phys. 68(1), 111-118 (2007). (Pubitemid 46589830)
79. Antonadou D, Coliarakis N, Synodinou ME et al. Randomized Phase III trial of radiation treatment ± amifostine in patients with advanced-stage lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 51(4), 915-922 (2001). (Pubitemid 33028882)
80. Senzer N. A Phase III randomized evaluation of amifostine in stage IIIA/IIIB non-small cell lung cancer patients receiving concurrent carboplatin, paclitaxel, and radiation therapy followed by gemcitabine and cisplatin intensification: preliminary findings. Semin. Oncol. 29(6 Suppl. 19), 38-41 (2002). (Pubitemid 36173245)
81. Antonadou D, Throuvalas N, Petridis AE, Bolanos N, Sagriotis A, Syridinou M. Effect of amifostine on toxicities associated with radiochemotherapy in patients with locally advanced non-small-cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 57(2), 402-408 (2003). (Pubitemid 37040936)
82. Leong SS, Tan EH, Fong KW, E et al. Randomized double-blind trial of combined modality treatment with or without amifostine in unresectable stage III non-small-cell lung cancer. J. Clin. Oncol. 21(9), 1767-1774 (2003).
83. Komaki R, Lee JS, Milas LE et al. Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial. Int. J. Radiat. Oncol. Biol. Phys. 58(5), 1369-1377 (2004). (Pubitemid 38438296)
84. Movsas B, Scott C, Langer CE et al. Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: Radiation Therapy Oncology Group trial 98-01. J. Clin. Oncol. 23(10), 2145-2154 (2005). (Pubitemid 46218706)
85. Sasse AD, Clark LG, Sasse EC, Clark OA. Amifostine reduces side effects and improves complete response rate during radiotherapy: results of a meta-analysis. Int. J. Radiat. Oncol. Biol. Phys. 64(3), 784-791 (2006).
86. Hensley ML, Hagerty KL, Kewalramani T et al. American society of clinical oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. J. Clin. Oncol. 27(1), 127-145 (2009). •• Overview and evidence-based recommendations on the use of protectants of side-effects in combined treatment.
87. Jeremic B. Low incidence of isolated nodal failures after involved-field radiation therapy for non-small-cell lung cancer: blinded by the light? J. Clin. Oncol. 25(35), 5543-5545 (2007).
88. Kepka L, Maciejewski B, Withers HR. Does incidental irradiation with doses lower than 50 Gy effectively reduce isolated nodal recurrences in non-small-cell lung cancer: dose-response relationship. Int. J. Radiat. Oncol. Biol. Phys. 73(5), 1391-1396 (2009).
89. Olaussen KA, Dunant A, Fouret P et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N. Engl. J. Med. 355(10), 983-991 (2006). (Pubitemid 44343542)
90. Booton R, Ward T, Ashcroft L, Morris J, Heighway J, Thatcher N. ERCC1 mRNA expression is not associated with response and survival after platinum-based chemotherapy regimens in advanced non-small cell lung cancer. J. Thorac. Oncol. 2(10), 902-906 (2007). (Pubitemid 47511592)